Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: A randomized trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Jong Hyeon | - |
dc.contributor.author | Kim, Minkyeong | - |
dc.contributor.author | Park, Suyeon | - |
dc.contributor.author | Jang, Wooyoung | - |
dc.contributor.author | Park, Jinse | - |
dc.contributor.author | Oh, Eungseok | - |
dc.contributor.author | Cho, Jin Whan | - |
dc.contributor.author | Kim, Ji Sun | - |
dc.contributor.author | Youn, Jinyoung | - |
dc.date.accessioned | 2021-09-10T06:49:43Z | - |
dc.date.available | 2021-09-10T06:49:43Z | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 1353-8020 | - |
dc.identifier.issn | 1873-5126 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/19501 | - |
dc.description.abstract | Background: The present study was a randomized, double-blind, placebo-controlled, multi-center trial to evaluate the efficacy and safety of prolonged-release melatonin (PRM) in Parkinson's disease (PD) patients with poor sleep quality. Methods: PD patients with a global Pittsburgh Sleep Quality Index (PSQI) score > 5 were included. Patients were assessed using the PSQI, a rapid eye movement sleep behavior disorder screening questionnaire, the Epworth Sleepiness Scale, Non-Motor Symptoms Scale (NMSS), Parkinson's Disease Quality of Life-39 (PDQ-39), and Unified Parkinson's Disease Rating Scale (UPDRS)-III at the beginning of the study and after 4 weeks of treatment with 2 mg of PRM. Partial correlation analysis was performed to investigate the relationship between PSQI score and the other scales. Results: Thirty-four PD patients with poor sleep quality were enrolled and divided into 2 groups based on medication; PRM (n = 16) and placebo (n = 18). Regarding efficacy, PSQI was significantly improved in the PRM group compared to the control group. Improvement in the NMSS and PDQ-39 summary index were observed in the PRM but not in the placebo group; UPDRS-III score was not significantly changed in either group. PSQI improvement correlated with improvement in NMSS score and PDQ-39 summary index. Regarding safety, all enrolled subjects did not complain of side effects due to PRM. Conclusion: PRM is an effective and safe treatment option for subjective sleep quality in PD patients and beneficial effects on sleep quality are associated with improved non-motor symptoms and quality of life in PD patients. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: A randomized trial | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1016/j.parkreldis.2020.03.029 | - |
dc.identifier.scopusid | 2-s2.0-85085498557 | - |
dc.identifier.wosid | 000557209100011 | - |
dc.identifier.bibliographicCitation | Parkinsonism and Related Disorders, v.75, pp 50 - 54 | - |
dc.citation.title | Parkinsonism and Related Disorders | - |
dc.citation.volume | 75 | - |
dc.citation.startPage | 50 | - |
dc.citation.endPage | 54 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.subject.keywordPlus | INSOMNIA | - |
dc.subject.keywordAuthor | Sleep disturbance | - |
dc.subject.keywordAuthor | Parkinson's disease | - |
dc.subject.keywordAuthor | Melatonin | - |
dc.subject.keywordAuthor | Circadian rhythm | - |
dc.subject.keywordAuthor | Prolonged-release melatonin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.